Acalabrutinib Is Not Associated With Increased Hypertension Risk in CLL

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension associated with the various BTK inhibitors, key findings from the cumulative review presented at the 2023 ASH Annual Meeting, and more.

Related Keywords

Houston ,Texas ,United States ,Alessandra Ferrajoli ,Division Of Cancer Medicine ,Department Of Leukemia ,University Of Texas Md Anderson Cancer Center ,Cancer Medicine ,Cancer Center ,Acalabrutinib ,Chronic Lymphocytic Leukemia ,Cll ,D ,Btk Inhibitors ,Hypertension ,Comorbidities ,